查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2000570

即時分子診斷市場：依產品類型、技術、應用和最終用戶分類－2026-2032年全球市場預測

Point of Care Molecular Diagnostics Market by Product Type, Technology, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，即時分子診斷市場價值將達到 56.4 億美元，到 2026 年將成長至 60.6 億美元，到 2032 年將達到 94.7 億美元，複合年成長率為 7.66%。

主要市場統計數據
基準年 2025 56.4億美元
預計年份：2026年 60.6億美元
預測年份 2032 94.7億美元
複合年成長率 (%) 7.66%

我們正在透過快速的即時分子診斷來塑造以患者為中心的未來照護模式，從而增強所有醫療保健環境中的臨床決策。

即時分子診斷技術透過快速、準確和分散式檢測，正在改變患者照護方式。小型化核酸擴增系統和數位連接技術的引入，加速了從集中式檢查室到床邊檢測環境的轉變。這種轉變使臨床醫生能夠在需要時做出明智的決策，縮短檢測結果返回時間，並最佳化治療方案。

技術創新和醫療服務模式變革推動了即時分子診斷技術的快速發展。

近年來，卓越的技術進步重塑了即時分子診斷的生態系統。微流體晶片設計和試劑配方的創新顯著縮短了檢測時間，使關鍵決策能夠在幾分鐘內而非幾小時內做出。同時，攜帶式硬體和雲端資料平台的整合實現了分散式檢查與中心檢查室網路之間的無縫連接。因此，臨床醫生現在可以結合患者病歷和人群健康指標，立即獲得可用的檢測結果。

評估 2025 年美國關稅措施對即時分子診斷供應鏈和成本結構的累積影響。

美國將於2025年實施更嚴格的關稅措施，這給即時分子診斷供應商和終端用戶帶來了新的挑戰。儀器及其耗材（如試劑盒和試劑盒）將面臨更高的進口關稅，這將直接影響其成本結構。為應對這項挑戰，製造商正在加快本地化生產並尋求替代採購契約，以降低利潤率下降的風險。

按產品類型、技術、應用和最終用戶對即時分子診斷市場進行關鍵細分分析。

對產品類型的全面分析表明，儀器銷售仍然是平台普及的基礎，這主要得益於設計和便攜性方面的持續創新。同時，隨著檢測項目擴展到多組檢測和新型生物標記物，試劑和試劑盒的需求仍然強勁。此外，隨著檢查室和醫療網路將數據分析和無縫互通性置於獨立硬體之上，對軟體產品的需求也在不斷成長。

闡明影響美洲、歐洲、中東和非洲以及亞太地區引入即時分子診斷的區域趨勢。

在美洲，對醫療基礎設施的持續投資和有利的法規環境正在加速都市區和農村即時分子診斷技術的應用。聯邦政府為加強疫情防範所做的努力已確保了快速檢測技術研發的資金支持，而私人醫療網路也在不斷擴大門診和社區健康中心的即時檢測能力。

揭示主要企業透過合作、合併和產品開發推動即時分子診斷創新的策略措施。

產業主要企業正優先考慮策略合作和收購，以拓展其即時分子診斷產品組合。大型診斷試劑開發商正與專業試劑生產商合作，共同開發專有檢測化學方法並最佳化供應鏈。同時，許多公司宣布收購軟體分析公司，以提升其分散式檢查網路的數據整合能力。

制定切實可行的建議，幫助產業領導者最大限度地利用即時分子診斷機會，增強其競爭優勢。

為了掌握分子檢測快速成長的需求，產業領導者應投資於支援模組化檢測擴充的靈活平台架構。設計能夠相容於多種試劑盒的系統，有助於機構快速應對新出現的病原體威脅和不斷變化的臨床需求。同樣重要的是，與試劑生產商建立策略合作夥伴關係，以確保高品質化學反應方法的穩定供應。

詳細介紹支持對即時分子診斷進行全面可靠分析的嚴謹調查方法。

本分析基於嚴謹的研究框架，結合了對多個地區高階主管、檢查室經理和臨床終端使用者的深入訪談。這些對話提供了關於即時分子診斷應用的具體採用者、技術偏好和營運挑戰的第一手資料。

概述即時分子診斷在現代醫學中的變革潛力和策略挑戰。

即時分子診斷融合了技術創新、臨床需求和經濟可行性。隨著平台變得更加緊湊、方便用戶使用和數位化連接，它們有望重新定義診斷流程，並在各種醫療環境中改善患者的治療效果。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 即時分子診斷市場：依產品類型分類

  • 裝置
  • 試劑和試劑盒
  • 軟體

第9章 即時分子診斷市場：依技術分類

  • 基因定序基礎
  • 雜合反應方法
  • 恒溫核酸增幅技術（INAAT）
  • 基於微陣列
  • 基於PCR的

第10章：即時分子診斷市場：依應用領域分類

  • 循環系統
  • 基因檢測
    • 攜帶者篩檢
    • 新生兒篩檢
    • 產前檢查
  • 感染疾病
    • 胃腸道感染疾病
    • 呼吸道感染疾病
    • 性行為感染傳染病
    • 熱帶病
  • 腫瘤學
    • 液態生物檢體
    • 突變譜分析
    • 致癌基因檢測

第11章 即時分子診斷市場：以最終用戶分類

  • 診所
  • 檢查室
  • 居家醫療環境
  • 醫院

第12章 即時分子診斷市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 即時分子診斷市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 即時分子診斷市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國即時分子診斷市場

第16章：中國即時分子診斷市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • ACON LABS INC.
  • Becton, Dickinson and Company
  • Binx Health, inc.
  • bioMerieux SA
  • Cardinal Health, Inc.
  • Chembio Diagnostics Inc.
  • Co-Diagnostics, Inc.
  • Danaher Corporation
  • DiaSorin SpA
  • EKF Diagnostics Holdings
  • FHoffmann-La Roche AG
  • Genomadix Inc. by LuminUltra Technologies Ltd.
  • Henry Schein, Inc.
  • Meridian Bioscience, Inc.
  • Novartis AG
  • OraSure Technologies, Inc.
  • Pfizer, Inc.
  • QIAGEN NV
  • Quidel Corporation
  • SD Biosensor
  • Sekisui Diagnostics
  • SHUWEN BIOTECH CO., LTD
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
Product Code: MRR-5A2C6AA669BE

The Point of Care Molecular Diagnostics Market was valued at USD 5.64 billion in 2025 and is projected to grow to USD 6.06 billion in 2026, with a CAGR of 7.66%, reaching USD 9.47 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.64 billion
Estimated Year [2026] USD 6.06 billion
Forecast Year [2032] USD 9.47 billion
CAGR (%) 7.66%

Unlocking the Future of Patient-Centered Care Through Rapid Point of Care Molecular Diagnostics That Enhance Clinical Decision Making Across Healthcare Settings

Point of care molecular diagnostics is transforming the delivery of patient care by enabling rapid, accurate, and decentralized testing. The introduction of miniaturized nucleic acid amplification systems combined with digital connectivity has accelerated the shift from centralized laboratories to bedside testing environments. This transition empowers clinicians to make informed decisions at the point of need, reducing turnaround times and optimizing treatment pathways.

Emerging assay formats leverage isothermal amplification, microfluidics, and integrated cartridge-based workflows to simplify sample preparation and analysis. As a result, healthcare professionals can detect infectious pathogens, genetic mutations, and oncological biomarkers in a fraction of the time required by traditional laboratory platforms. This evolution aligns with the broader trend toward personalized medicine, where diagnostic insights drive targeted therapies and improve clinical outcomes.

Furthermore, evolving reimbursement frameworks and regulatory guidelines have catalyzed the adoption of these devices in diverse care settings. Strategic collaborations between diagnostic developers, healthcare institutions, and digital health companies are fostering interoperability and data integration, creating an ecosystem that supports real-time surveillance and longitudinal patient monitoring.

The lessons learned from global pandemic responses have underscored the critical importance of rapid molecular detection in controlling outbreaks and mitigating public health risks. By deploying portable diagnostic units in field settings and resource-limited environments, stakeholders can identify and contain emerging threats before they spread. Consequently, this capability not only enhances the resilience of healthcare systems but also supports broader public health initiatives aimed at disease surveillance and prevention.

Charting the Rapid Evolution of Point of Care Molecular Diagnostics Driven by Technological Innovation and Shifting Healthcare Delivery Models

Recent years have witnessed remarkable technological advances that are reshaping the point of care molecular diagnostics ecosystem. Innovations in microfluidic chip design and reagent formulation have dramatically reduced assay turnaround times, allowing critical decisions to be made within minutes rather than hours. Simultaneously, the integration of portable hardware with cloud-based data platforms is enabling seamless connectivity between decentralized test sites and central laboratory networks. As a result, clinicians benefit from immediate access to actionable test results alongside patient histories and population health metrics.

Concurrently, the rise of machine learning and artificial intelligence has begun to inform assay interpretation and workflow optimization. Predictive algorithms can now help flag inconsistent assay outputs, standardize quality control, and even suggest differential diagnoses based on molecular signatures. These capabilities not only improve analytical accuracy but also reduce the burden on healthcare professionals, who face increasing pressures related to staffing shortages and rising case volumes.

Regulatory bodies and payers are responding to these shifts by streamlining approval pathways and updating reimbursement codes to reflect the value proposition of rapid molecular assays. In parallel, healthcare systems are exploring value-based care models that incentivize the reduction of hospital stays and readmissions through timely diagnostics. Taken together, these transformative forces are charting a new era in which point of care molecular testing becomes an indispensable component of efficient, patient-centered healthcare delivery.

Assessing the Cumulative Impact of 2025 United States Tariff Measures on Point of Care Molecular Diagnostics Supply Chains and Cost Structures

The imposition of enhanced tariff measures by the United States in 2025 has introduced a new set of challenges for suppliers and end users of point of care molecular diagnostics. Instruments, along with their consumable reagents and kits, are facing increased import duties that directly impact cost structures. In response, manufacturers are accelerating efforts to localize production and secure alternative sourcing agreements, thereby mitigating the risk of margin erosion.

As reagents become subject to higher duties, distributors and diagnostic laboratories are reevaluating inventory strategies and pricing models. Some organizations have begun renegotiating long-term contracts to achieve volume-based discounts or to shift toward vendor-managed inventory solutions that reduce holding costs. Despite these adjustments, smaller clinics and home care providers may experience delayed adoption of new assays due to constrained budgets and tighter procurement cycles.

Yet, amid these headwinds, a silver lining has emerged: renewed interest in domestic supply chain resilience. Stakeholders are exploring partnerships with contract manufacturing organizations and establishing regional distribution hubs to shorten lead times and reduce exposure to global logistics disruptions. Ultimately, the 2025 tariff environment is prompting a strategic realignment across the value chain as industry participants strive to balance cost pressures against the imperative for rapid, reliable molecular diagnostics.

Illuminating Key Segmentation Insights Across Product Types Technologies Applications and End Users in the Point of Care Molecular Diagnostics Market

A comprehensive examination of product categories reveals that instrument sales continue to serve as a cornerstone for platform adoption, driven by ongoing innovations in design and portability. At the same time, reagents and kits are experiencing robust demand as assay menus expand to include multiplex panels and novel biomarkers. Software offerings, meanwhile, are gaining traction as laboratories and care networks prioritize data analytics and seamless interoperability over standalone hardware.

When analyzing technological underpinnings, genetic sequencing-based approaches have begun to penetrate the point of care arena by offering comprehensive genomic insights in near real time. Hybridization-based methods maintain their stronghold in targeted applications, while isothermal nucleic acid amplification technology provides cost-effective, rapid detection in resource-constrained environments. Furthermore, microarray-based solutions are carving out niches in specialized diagnostics, and PCR-based platforms remain the predominant choice for high-sensitivity assays.

In terms of clinical applications, cardiology assays are emerging as a critical tool for identifying acute cardiac events and guiding treatment pathways. Genetic testing has diversified beyond traditional carrier screening to encompass newborn and prenatal diagnostics, delivering actionable information earlier in the patient journey. Infectious disease testing continues to evolve with expanded panels for gastrointestinal, respiratory, sexually transmitted, and tropical pathogens. Oncology has witnessed significant growth in liquid biopsy techniques, mutation profiling, and onco-gene panels that support personalized cancer management.

Finally, end user dynamics underscore a shift toward decentralized models. Clinics are investing in compact systems to deliver same-visit results, whereas diagnostic laboratories reinforce centralized capabilities with point of care extensions. Home care settings are piloting user-friendly devices that enable remote monitoring, and hospitals are integrating molecular diagnostics into emergency and surgical workflows to enhance patient throughput.

Revealing Regional Dynamics Shaping Adoption of Point of Care Molecular Diagnostics Across the Americas Europe Middle East and Africa and Asia-Pacific

In the Americas, sustained investment in healthcare infrastructure and a supportive regulatory environment have accelerated the deployment of point of care molecular diagnostics across both urban and rural settings. Federal initiatives aimed at strengthening pandemic preparedness have unlocked funding for rapid test development, while private healthcare networks continue to expand point of care capabilities within ambulatory care and community health centers.

Across Europe Middle East and Africa, diverse regulatory landscapes present both challenges and opportunities. In Western Europe, harmonized approval processes and robust reimbursement schemes have fostered early adoption of advanced molecular platforms. Meanwhile, in emerging markets, flexible pricing models and public-private partnerships are instrumental in scaling assay deployment. Regions facing infrastructure limitations are increasingly leveraging portable, battery-powered devices to bridge diagnostic gaps.

Asia-Pacific is witnessing some of the fastest growth rates globally, fueled by large patient populations and proactive government initiatives focused on disease surveillance. Economic growth in key markets has led to enhanced healthcare spending, while innovative payment models-such as subscription-based reagent plans-are unlocking access in mid-tier hospitals and clinics. Additionally, collaborations with local manufacturers are reducing costs and expediting market entry for new assays.

Uncovering Strategic Moves of Leading Players Driving Innovation in Point of Care Molecular Diagnostics Through Partnerships Mergers and Product Development

Leading industry participants are prioritizing strategic collaborations and acquisitions to broaden their point of care molecular diagnostics portfolios. Major diagnostic developers are forging partnerships with specialty reagent producers to co-develop proprietary assay chemistries and streamline supply chains. Simultaneously, a number of players have announced bolt-on acquisitions of software analytics firms to elevate data integration capabilities across decentralized testing networks.

On the innovation front, several organizations are piloting next-generation sequencing modules that can be tethered to mobile workstations, thereby bringing comprehensive genomic profiling to outpatient settings. Other companies are doubling down on isothermal amplification technology, aiming to deliver low-cost, high-throughput solutions amenable to field deployment in emerging markets. Across the board, differentiated assay sensitivity and specificity have become key competitive levers.

Moreover, an increasing emphasis on digital health has prompted diagnostic vendors to bundle connectivity services, offering cloud-based result management and remote quality-control dashboards. This shift is reshaping go-to-market strategies as customers demand turnkey solutions that encompass hardware, consumables, and software under unified service agreements.

Formulating Actionable Recommendations for Industry Leaders to Capitalize on Opportunities in Point of Care Molecular Diagnostics and Enhance Competitive Advantage

To capitalize on the growing demand for rapid molecular testing, industry leaders should invest in flexible platform architectures that support modular assay expansion. By designing systems capable of accommodating a wide range of reagent cartridges, organizations can swiftly respond to emerging pathogen threats and shifting clinical priorities. Equally important is the cultivation of strategic alliances with reagent manufacturers to ensure a reliable supply of high-quality chemistries.

Furthermore, aligning product development roadmaps with evolving regulatory frameworks and reimbursement pathways will expedite market access. Cross-functional task forces that include regulatory experts, clinical liaisons, and health economics professionals can proactively address compliance requirements and articulate value propositions to payers. In parallel, establishing training programs and remote support capabilities will enhance user adoption and minimize operator errors in decentralized environments.

Finally, enhancing supply chain resilience through the localization of key manufacturing processes and the creation of regional distribution hubs will mitigate the impact of future trade disruptions. Coupling these efforts with data-driven demand forecasting tools will optimize inventory levels and reduce lead times. By adopting these measures, decision-makers can secure a competitive edge while delivering reliable point of care diagnostics to a broad spectrum of end users.

Detailing the Rigorous Research Methodology Underpinning the Analysis for Comprehensive and Reliable Point of Care Molecular Diagnostics Insights

This analysis is grounded in a rigorous research framework that combines in-depth primary interviews with senior executives, laboratory directors, and clinical end users across multiple geographies. These conversations provided first-hand insights into adoption drivers, technology preferences, and operational challenges specific to point of care molecular applications.

Secondary research complemented these qualitative findings by drawing on peer-reviewed publications, regulatory filings, and corporate release documents. Data from industry whitepapers and public health agency reports were triangulated against proprietary databases to validate trends and ensure consistency. Each data point underwent cross-verification through multiple sources to maintain accuracy and objectivity.

Our segmentation approach aligns product types, technology modalities, clinical applications, and end user categories to deliver a nuanced understanding of market dynamics. Regional analyses were informed by economic indicators, healthcare spending patterns, and local regulatory landscapes. Key performance metrics and thematic insights were further tested through scenario planning exercises to assess resilience under varying market conditions.

Quality control measures-including independent peer reviews, editorial audits, and methodological sanity checks-ensure that findings meet the highest standards of reliability. The resulting perspectives offer stakeholders a robust foundation for strategic decision-making and informed investment in point of care molecular diagnostics.

Concluding Perspectives on the Transformative Potential and Strategic Imperatives of Point of Care Molecular Diagnostics in Modern Healthcare

Point of care molecular diagnostics stands at the intersection of technological innovation, clinical necessity, and economic pragmatism. As platforms become more compact, user friendly, and digitally connected, they have the potential to redefine diagnostic workflows and enhance patient outcomes across diverse care settings.

Industry participants must remain vigilant in adapting to shifting regulatory requirements, supply chain challenges, and evolving reimbursement landscapes. By embracing strategic partnerships, investing in modular architectures, and aligning closely with clinical stakeholders, organizations can harness the transformative power of rapid molecular testing. Ultimately, those who proactively integrate these solutions into healthcare delivery models will lead the migration toward faster, more personalized care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Point of Care Molecular Diagnostics Market, by Product Type

  • 8.1. Instruments
  • 8.2. Reagents & Kits
  • 8.3. Software

9. Point of Care Molecular Diagnostics Market, by Technology

  • 9.1. Genetic Sequencing-based
  • 9.2. Hybridization-based
  • 9.3. Isothermal Nucleic Acid Amplification Technology (INAAT)
  • 9.4. Microarray-based
  • 9.5. PCR-based

10. Point of Care Molecular Diagnostics Market, by Application

  • 10.1. Cardiology
  • 10.2. Genetic Testing
    • 10.2.1. Carrier Screening
    • 10.2.2. Newborn Screening
    • 10.2.3. Prenatal Testing
  • 10.3. Infectious Disease
    • 10.3.1. Gastrointestinal Infections
    • 10.3.2. Respiratory Infections
    • 10.3.3. Sexually Transmitted Infections
    • 10.3.4. Tropical Diseases
  • 10.4. Oncology
    • 10.4.1. Liquid Biopsy
    • 10.4.2. Mutation Profiling
    • 10.4.3. Oncogene Panel

11. Point of Care Molecular Diagnostics Market, by End User

  • 11.1. Clinics
  • 11.2. Diagnostic Laboratories
  • 11.3. Home Care Settings
  • 11.4. Hospitals

12. Point of Care Molecular Diagnostics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Point of Care Molecular Diagnostics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Point of Care Molecular Diagnostics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Point of Care Molecular Diagnostics Market

16. China Point of Care Molecular Diagnostics Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. ACON LABS INC.
  • 17.7. Becton, Dickinson and Company
  • 17.8. Binx Health, inc.
  • 17.9. bioMerieux SA
  • 17.10. Cardinal Health, Inc.
  • 17.11. Chembio Diagnostics Inc.
  • 17.12. Co-Diagnostics, Inc.
  • 17.13. Danaher Corporation
  • 17.14. DiaSorin S.p.A
  • 17.15. EKF Diagnostics Holdings
  • 17.16. FHoffmann-La Roche AG
  • 17.17. Genomadix Inc. by LuminUltra Technologies Ltd.
  • 17.18. Henry Schein, Inc.
  • 17.19. Meridian Bioscience, Inc.
  • 17.20. Novartis AG
  • 17.21. OraSure Technologies, Inc.
  • 17.22. Pfizer, Inc.
  • 17.23. QIAGEN N.V.
  • 17.24. Quidel Corporation
  • 17.25. SD Biosensor
  • 17.26. Sekisui Diagnostics
  • 17.27. SHUWEN BIOTECH CO., LTD
  • 17.28. Siemens Healthineers AG
  • 17.29. Sysmex Corporation
  • 17.30. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC SEQUENCING-BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC SEQUENCING-BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC SEQUENCING-BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY HYBRIDIZATION-BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY HYBRIDIZATION-BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY HYBRIDIZATION-BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAY-BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAY-BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAY-BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR-BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR-BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR-BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CARRIER SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CARRIER SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CARRIER SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEWBORN SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEWBORN SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEWBORN SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TROPICAL DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TROPICAL DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TROPICAL DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY LIQUID BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY LIQUID BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY LIQUID BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MUTATION PROFILING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MUTATION PROFILING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MUTATION PROFILING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOGENE PANEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOGENE PANEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOGENE PANEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. GCC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. GCC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. GCC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 164. GCC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 165. GCC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 166. GCC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 167. GCC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 168. GCC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. G7 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. G7 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. G7 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 188. G7 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 189. G7 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 190. G7 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 191. G7 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 192. G7 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. NATO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. NATO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. NATO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 196. NATO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 197. NATO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 198. NATO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 199. NATO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 200. NATO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. CHINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)